Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study

References

• US Department of Health and Human Services [webpage on the Internet]Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents: US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (a Working Group of the Office of AIDS Research Advisory Council)2014 [updated May 1; cited October 7, 2014]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdfAccessed March 1, 2016
   Google Scholar
• GazzardBGAndersonJBabikerABHIVA Treatment Guidelines Writing GroupBritish HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008HIV Med2008956360818826546
   PubMed Web of Science ®Google Scholar
• WilliamsIChurchillDAndersonJBritish HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)HIV Med201415suppl 1185
   Google Scholar
• Ministero della Salute [webpage on the Internet]Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV 2013 [updated November; cited November 25, 2014] Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2074_allegato.pdfAccessed March 1, 2016
   Google Scholar
• European AIDS Clinical Society [webpage on the Internet]EACS Guidelines Version 7.0 2014 [updated October; cited 2014 November 25]. Available from: http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdfAccessed March 1, 2016
   Google Scholar
• Janssen-Cilag International NVPrezista (Darunavir). Summary of Product Characteristics 2016 [updated December 12, 2015] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000707/WC500041756.pdfAccessed March 18, 2016
   Google Scholar
• PhungBCYeniPDarunavir: an effective protease inhibitor for HIV-infected patientsExpert Rev Anti Infect Ther2011963164321692667
   PubMed Web of Science ®Google Scholar
• McKeageKPerryCMKeamSJDarunavir: a review of its use in the management of HIV infection in adultsDrugs20096947750319323590
   PubMed Web of Science ®Google Scholar
• DeeksEDDarunavir: a review of its use in the management of HIV-1 infectionDrugs2014749912524338166
   PubMed Web of Science ®Google Scholar
• OrtizRDejesusEKhanlouHEfficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48AIDS2008221389139718614861
   PubMed Web of Science ®Google Scholar
• MillsAMNelsonMJayaweeraDOnce-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAIDS2009231679168819487905
   PubMed Web of Science ®Google Scholar
• PozniakAOpravilMBeattyGHillAde BethuneMPLefebvreEEffect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2AIDS Res Hum Retroviruses2008241275128018844462
   PubMed Web of Science ®Google Scholar
• ArastehKYeniPPozniakAEfficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96Antivir Ther20091485986419812449
   PubMed Web of Science ®Google Scholar
• CahnPFourieJGrinsztejnBWeek 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patientsAIDS20112592993921346512
   PubMed Web of Science ®Google Scholar
• MadrugaJVBergerDMcMurchieMTITAN Study GroupEfficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trialLancet2007370495817617272
   PubMed Web of Science ®Google Scholar
• OrkinCDeJesusEKhanlouHFinal 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trialHIV Med201314495923088336
   PubMed Web of Science ®Google Scholar
• BanhegyiDKatlamaCda CunhaCAWeek 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITANCurr HIV Res20121017118122339125
   PubMed Web of Science ®Google Scholar
• LathouwersEDe MeyerSDierynckIVirological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysisAntivir Ther2011169910821311113
   PubMed Web of Science ®Google Scholar
• PodzamczerDImazAPerezIKIDAR Study GroupAbacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patientsJ Antimicrob Chemother2014692536254024833755
   PubMed Web of Science ®Google Scholar
• MenzaghiBRicciECarenziLSafety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)Biomed Pharmacother20136729329823433852
   PubMed Web of Science ®Google Scholar
• BeneaOEStreinu-CercelADorobatCEfficacy and safety of darunavir (Prezista(R)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective studyGerms20144596925276665
   PubMedGoogle Scholar
• GatheJExperience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single centerCurr Med Res Opin20082476977318234149
   PubMed Web of Science ®Google Scholar
• RibeiroKMBiscioneFMWestinMRMachadoDPGrecoDBTupinambasUVirologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort studyBraz J Infect Dis2014181723916454
   PubMed Web of Science ®Google Scholar
• WilligJHAbanINevinCRDarunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeksAIDS Res Hum Retroviruses2010261279128520961276
   PubMed Web of Science ®Google Scholar
• KimHPerelsonASViral and latent reservoir persistence in HIV-1-infected patients on therapyPLoS Comput Biol20062e13517040122
   PubMed Web of Science ®Google Scholar
• MolinaJMCohenCKatlamaCTMC114-C208 Study Group; TMC114-C215 Study GroupSafety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3J Acquir Immune Defic Syndr200746243117621237
   PubMed Web of Science ®Google Scholar
• De MeyerSMSpinosa-GuzmanSVangeneugdenTJde BethuneMPMirallesGDEfficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavirJ Acquir Immune Defic Syndr20084917918218769351
   PubMed Web of Science ®Google Scholar
• ClotetBBellosNMolinaJMPOWER 1 and 2 Study GroupsEfficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsLancet20073691169117817416261
   PubMed Web of Science ®Google Scholar
• BerhanABerhanYVirologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trialsPLoS One20138e6081423593314
   PubMed Web of Science ®Google Scholar
• RaffiFBabikerAGRichertLNEAT001/ANRS143 Study GroupRitonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trialLancet20143841942195125103176
   PubMed Web of Science ®Google Scholar